Lukas Hainz

Within the burgeoning field of regenerative medicine, the value of umbilical cord blood as a potent and ethically sound source of life-saving stem cells is universally recognized, offering transformative treatments for a spectrum of conditions from genetic disorders to hematologic cancers. The

We're speaking with biopharma expert Ivan Kairatov about a groundbreaking study that uses artificial intelligence to decode one of the immune system's fundamental secrets: how antibodies are built. For decades, a key assumption about antibody assembly has shaped therapeutic design, but a new AI

A groundbreaking artificial intelligence tool is poised to redefine the treatment landscape for oropharyngeal cancer, offering a new level of precision that could spare patients from unnecessarily harsh therapies while ensuring high-risk individuals receive the aggressive care they need. Developed

A ghost from medicine's past, a chemical once notorious for its lethal side effects in the pursuit of weight loss, is being cautiously resurrected by scientists aiming to solve the modern obesity crisis. This ambitious endeavor revisits a century-old idewhat if a drug could make the human body

Deep within the microscopic confines of every human cell, a biological masterpiece unfolds not as a simple string of code but as a dynamic, three-dimensional sculpture that dictates life itself. A landmark study has now provided the most detailed and extensive atlas of this hidden architecture,

The landscape of virtual healthcare has entered a new and complex phase, where the rules governing patient access and provider reimbursement are no longer uniform across the board. In a significant move that underscores a growing divergence from federal guidelines, UnitedHealthcare announced on

For decades, the cellular machinery responsible for building life’s essential proteins was viewed as a simple, unguided assembly line, but new evidence suggests a sophisticated manager has been overseeing the entire operation all along. This molecular coordinator, known as the nascent

In the complex landscape of global health, few challenges are as daunting as tackling late-stage cancer diagnoses in regions with limited resources. Ivan Kairatov, a biopharma expert whose work sits at the intersection of technological innovation and public health, has been at the forefront of a

The European health sector is currently navigating a period of unprecedented transformation, where landmark legislative reforms and a surge in therapeutic innovation are converging to redefine the future of medicine regulation. As the European Medicines Agency (EMA) marks its 30th anniversary, it

The cutting edge of cancer treatment often involves a delicate and high-stakes balance between revolutionary efficacy and severe, sometimes fatal, side effects. This reality has been starkly highlighted as a pivotal late-stage clinical trial for a promising new cancer therapy, ifinatamab deruxtecan